Pancreatic Cancer Research

ResearcherCold Spring Harbor LaboratoryActive in the last 2 years

Chang‐Il Hwang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5710-7672; OpenAlex author ID A5051180471; NIH RePORTER profile ID 11286845. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 7)
Trials
0
Grants
3
Labs led
1
Collaborators
102
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers, 1 grant · 2018: none · 2019: 1 paper · 2020: 2 papers, 1 grant · 2021: 3 papers · 2022: 5 papers · 2023: 2 papers · 2024: 5 papers · 2025: 1 paper · 2026: 1 grant

Papers 24

  1. Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology. Last author DOI 10.1038/s12276-024-01378-w↗
  2. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Last author DOI 10.1002/advs.202308537↗
  3. Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer. Last author DOI 10.1016/j.isci.2024.109414↗
  4. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  5. Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application. Last author DOI 10.3390/biom14111381↗
  6. Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/epigenomes8040041↗
  7. A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. Last author DOI 10.1038/s41419-023-06145-9↗
  8. KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. Co-author DOI 10.1038/s41467-023-41297-4↗
  9. Genomic heterogeneity in pancreatic cancer organoids and its stability with culture. Co-author DOI 10.1038/s41525-022-00342-9↗
  10. A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice. Co-author DOI 10.1158/2767-9764.crc-22-0256↗
  11. Correction: A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice. Co-author DOI 10.1158/2767-9764.crc-22-0510↗
  12. SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment. Co-author DOI 10.3389/fonc.2022.890154↗
  13. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Co-author DOI 10.3390/cancers14133239↗
  14. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Co-author DOI 10.1038/s41467-021-23731-7↗
  15. EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer. Co-author DOI 10.1093/narcan/zcab023↗
  16. Epigenetic Alterations in Pancreatic Cancer Metastasis. Last author DOI 10.3390/biom11081082↗
  17. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Co-author DOI 10.1084/jem.20192389↗
  18. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  19. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  20. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. First author DOI 10.1016/j.cell.2017.07.007↗
  21. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  22. Preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.4651↗
  23. Model organoids provide new research opportunities for ductal pancreatic cancer. First author DOI 10.1080/23723556.2015.1014757↗
  24. Organoid models of human and mouse ductal pancreatic cancer. First author DOI 10.1016/j.cell.2014.12.021↗

Grants 3

  1. Engrailed-1 and Epigenetic Vulnerabilities in Metastatic Pancreatic Cancer R37CA249007↗
  2. Identification of Key Regulators in Pancreatic Cancer Metastasis K22CA226037↗
  3. The Characterization of the New Tumor Suppressor USP9X in Pancreatic Cancer F32CA180717↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Arthur Tuveson · 11 shared papers, 2015–2024 · strength 0.94
  2. Jihao Xu · 5 shared papers, 2021–2025 · strength 0.90
  3. Vincenzo Corbo · 6 shared papers, 2015–2025 · strength 0.76
  4. Eunjung Lee · 3 shared papers, 2023–2024 · strength 0.65
  5. Peinan Liu · 2 shared papers, 2024 · strength 0.64
  6. Youngkyu Park · 7 shared papers, 2015–2024 · strength 0.53
  7. Tobiloba E. Oni · 5 shared papers, 2015–2025 · strength 0.52
  8. Hervé Tiriac · 6 shared papers, 2015–2024 · strength 0.44
  9. Suyakarn Archasappawat · 2 shared papers, 2023–2024 · strength 0.44
  10. Mariano Ponz‐Sarvisé · 4 shared papers, 2015–2025 · strength 0.44
  11. Daniel Öhlund · 4 shared papers, 2015–2025 · strength 0.44
  12. Sarah S. Wang · 2 shared papers, 2021–2024 · strength 0.40
  13. Lindsey A. Baker · 6 shared papers, 2015–2020 · strength 0.39
  14. Christopher R. Vakoc · 4 shared papers, 2017–2024 · strength 0.37
  15. Jae‐Seok Roe · 3 shared papers, 2017–2024 · strength 0.33
  16. Natalia E. Cortez · 2 shared papers, 2022 · strength 0.27
  17. Cecilia Rodríguez Lanzi · 2 shared papers, 2022 · strength 0.27
  18. Gerardo Guillermo Mackenzie · 2 shared papers, 2022 · strength 0.27
  19. Claudia Tonelli · 2 shared papers, 2020–2024 · strength 0.24
  20. Hans C. Clevers · 4 shared papers, 2015–2017 · strength 0.24
  21. Dannielle D. Engle · 4 shared papers, 2015–2019 · strength 0.22
  22. Edward Jae-Hoon Kim · 2 shared papers, 2017–2022 · strength 0.22
  23. Tim D.D. Somerville · 3 shared papers, 2017–2020 · strength 0.21
  24. Jean L. Grem · 2 shared papers, 2017–2024 · strength 0.21
  25. Michael Anthony Hollingsworth · 2 shared papers, 2017–2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.